Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 11/20 | 0.61 |
| ▸ | CDK1 | P06493 | 11/20 | 0.61 |
| ▸ | CCNB1 | P14635 | 11/20 | 0.61 |
| ▸ | CCNB3 | Q8WWL7 | 11/20 | 0.61 |
| ▸ | GSK3B | P49841 | 10/20 | 0.61 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.61 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.61 |
| ▸ | GSK3A | P49840 | 9/20 | 0.56 |
| ▸ | TBK1 | Q9UHD2 | 9/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1780492 | 0.90 | CCNB2 (0.54) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL1778600 | 0.89 | CCNB2 (0.59) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL1778221 | 0.86 | PIM1 (0.65) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL1780576 | 0.81 | CCNB2 (0.53) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL13503102 | 0.81 | TBK1 (0.45) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL13495429 | 0.77 | PIK3CD (0.53) | TBK1 | |
| SCHEMBL1779136 | 0.74 | CCNB2 (0.90) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL28129326 | 0.74 | CSF1R (0.50) | TBK1 | |
| SCHEMBL15586894 | 0.74 | CSF1R (0.62) | TBK1 | |
| SCHEMBL491029 | 0.72 | CCNB2 (1.00) | CCNB2CDK1CCNB1CCNB3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048540-A1 | Heterocyclic N-Oxides as Hypoxic Selective Protein Kinase Inhibitors | SENTINEL ONCOLOGY LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048540-A1 | Heterocyclic N-Oxides as Hypoxic Selective Protein Kinase Inhibitors | HIF1AN, HIF1A, HYOU1 | CCNB2 499/4885CDK1 19/4885CCNB1 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.